Detalhe da pesquisa
1.
Neutralization, effector function and immune imprinting of Omicron variants.
Nature
; 621(7979): 592-601, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37648855
2.
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
Antimicrob Agents Chemother
; 66(5): e0203821, 2022 05 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35389236
3.
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Clin Infect Dis
; 73(2): e485-e493, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32668455
4.
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
J Antimicrob Chemother
; 76(8): 2153-2157, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33880558
5.
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Antimicrob Agents Chemother
; 63(5)2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30803969
6.
Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping.
J Acquir Immune Defic Syndr
; 93(3): 213-218, 2023 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36961945
7.
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.
EClinicalMedicine
; 59: 101991, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37200995
8.
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
bioRxiv
; 2023 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36711984
9.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
J Acquir Immune Defic Syndr
; 89(4): 433-440, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34897227
10.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
AIDS
; 36(11): 1511-1520, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35466963
11.
Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
J Acquir Immune Defic Syndr
; 86(3): 369-377, 2021 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33196554
12.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
J Acquir Immune Defic Syndr
; 85(3): 363-371, 2020 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32701823
13.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Lancet HIV
; 7(6): e389-e400, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32504574
14.
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
J Acquir Immune Defic Syndr
; 82(3): 321-328, 2019 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31609930
15.
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 6(6): e355-e363, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31068270
16.
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 6(6): e364-e372, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31068272
17.
HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
J Acquir Immune Defic Syndr
; 79(1): e45-e51, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29781878